Background: Intra-articular corticosteroid injection is a well-established procedure in the daily practice since many decades [1] . High-resolution ultrasound (US), considered as in vivo microscopy, has the potential to help to understand how drugs develop their anti-inflammatory properties inside the articular space [2] . Objectives: To provide a very tight sonographic monitoring of the changes in a single metacarpophalangeal (MCP) joint in rheumatoid arthritis (RA) patients after the administration of intra-articular corticosteroid. Methods: In this study we consecutively enrolled RA patients with active disease (Composite Disease Activity Index -CDAI >10), at least one tender and swollen MCP joint, and without contraindication to intra-articular corticosteroid injection (e.g. poor controlled diabetes). After the clinical evaluation that established the most clinically involved MCP joint to inject, patients underwent an US examination of the joint by an experienced sonographer. Synovitis was scored in grey scale (GS) in terms of joint space enlargement (measured at the level where the distance between the bone diaphysis and the joint capsule was greater), and power Doppler (PD) signal (scored by a semiquantitative method: 0 = no intraarticular flow, 1 = single vessel signal, 2 = confluent vessels, and 3 = vessel signal in more than 50% of the intra-articular area). After the baseline US assessment (T0), the MCP joints were injected with 20 mg triamcinolone acetonide under sonographic guidance. Sonographic follow-up was performed in five timepoints: two hours (T1) after the injection, four hours (T2), eight hours (T3), 24 hours (T4), and 48 hours after the injection (T5). Results: Fifteen patients (13 women), with a mean age of 62.5 years, completed the follow-up. The mean CDAI was 28.9, anti-citrullinated protein antibodies were present in 9 patients. At T5, in all the patients was detectable a global reduction of joint space enlargement, of intra-articular PD signal, and of the numerical rating scale (NRS) of pain at the joint injected (Table) . However, in majority of the patients (n: 13), the joint space enlargement showed an increase in the T1 and T2 US examinations, and in four patients PD signal, compared to T0, increased within the eight hours after the injection. No major adverse events were registered. Conclusions: A single intra-articular corticosteroid injection, performed under US guidance, is a very fast treatment to reduce synovitis of the injected joint. In the hours next to the injection is common to reveal a rise of joint space enlargement together with that of PD signal score. (Fig.1a) . We observed a significant difference in drug survival between early RA pts 63 (16) wks) and early SpA pts 112,7 (15,8) wks (p=0,001) (Fig.1b) . In 55% early RA pts and in 45% early SpA pts the biotechnology drug needs to be added because of disease flare. In the remaining pts a low disease activity (DAS≤3,2) was observed. No adverse events were recorded in follow-up period. In early RA pts predictors of shorter MTXm survival were younger age at diagnosis (p=0,004), lower dose of MTX (p=0,032), earlier diagnosis from symptom onset (p=0,0001), higher titer of rheumatoid factor (p=0,037) and female gender (p=0,019). In early SpA pts the only predictor of shorter MTXm survival was younger age at diagnosis (p=0,0,37). Smoking, disease activity at diagnosis and BMI were not predictors of MTXm survival.
Conclusions:
The MTXm survival is not influenced by VEA or EA diagnosis. The RA seems to be less responder to MTXm than SpA. It might be due to the difficult to capture the earliest phase of disease, as circulating antibodies might appear years before the onset of symptoms in RA, and biomarkers reflecting bone destruction are elevated before arthritis is present, as described in previous studies. In particular, might be pay attention to younger pts, female gender and pts with higher titer of rheumatoid factor as they seem to present a more resistant RA disease. A high dose of MTX and earlier interventions are suggested in RA to improve the clinical outcome of patients and the MTXm survival. Background: An increase in the number of anti-citrullinated protein antibodies (ACPA) reactivities precede RA onset, and may be involved in the pathogenesis of the disease. The presence of ACPA is associated with radiographic progression in RA, and it has been suggested that ACPAs with different reactivities may be associated with different phenotypes of RA. Objectives: To assess the prevalence of baseline ACPA reactivities in an inception cohort of early RA patients, including subgroups based on anti-CCP/RF status, and to compare the findings to healthy controls. Methods: 217 DMARD-naïve early RA patients from the ARCTIC trial (1) were analysed. Radiographs were scored according to van der Heijde Sharp (vdHS) score. Anti-CCP status was analysed by FEIA (pos. if ≥10 IU/mL) and RF by ELISA (pos. if ≥25 IU/mL). ACPA titres (AU/ml) were considered pos. if above the 98-perc. of values in 619 non-RA subjects. Analysis of 13 ACPA reactivities targeting citrullinated peptides from fibrinogen, alpha-1 enolase, vimentin, fillagrin and histone was performed at baseline in patients and 94 controls (blood donors matched for age/gender/smoking), using a multiplex chip-based assay (2). 
